Here are the DEF 14A proxy statements from Aclaris Therapeutics, Inc. (ACRS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ACRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRS filings page.
Aclaris Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders on June 4, 2026 at 9:00 a.m. Eastern Time. Stockholders of record as of April 14, 2026, holding 139,663,680 shares of common stock, may vote online using a 16-digit control number.
Three items are up for vote: electing two directors (Anand Mehra and Maxine Gowen) for terms ending in 2029, an advisory “say-on-pay” vote on executive compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026. The board is classified into three classes and currently has eight members, six of whom are independent under Nasdaq rules.
The proxy details 2025 pay for named executive officers, including total compensation of $3,375,591 for CEO Neal Walker, $1,490,790 for CFO Kevin Balthaser, and $1,447,106 for Chief Business Officer James Loerop, combining salary, stock awards, options and bonuses. It also discloses major shareholders such as BML Investment Partners at 10.2% and Biosion, Inc. at 8.1%, outlines board committee responsibilities, insider trading and clawback policies, and explains how votes, broker non-votes and quorum (69,831,841 shares) are determined.